Key points are not available for this paper at this time.
This is the first study to describe adalimumab pharmacokinetics and the concentration-effect relationship in RA. A 160 mg loading dose may lead to an increased benefit from treatment in RA patients.
Ternant et al. (Tue,) studied this question.